An official website of the United States government
Substances
Topics
- Substance Misuse Prevention
- Tobacco Smoke & Health
- Fetal Alcohol Spectrum Disorders (FASD)
- Alcohol Misuse and Alcohol Use Disorder
- Underage Drinking
- Cannabidiol Research
- Cannabinoid Research
- Cocaine
- Electronic Nicotine Delivery Systems
- Endocannabinoid System Research
- Fentanyl Misuse & Addiction
- Harm Reduction for Substance Misuse
- Methamphetamine
- Opioid Misuse & Addiction
- Opioids
- Prescription Drug Misuse
- Recovery Support Services
- Screening & Brief Intervention for Substance Misuse
- Stimulant Use and Misuse
- Substance Misuse
- Therapeutic Cannabinoid Research
- Tobacco
Extended-Release vs Sublingual Buprenorphine for Adolescent Opioid Use Disorder (ERA) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S.
This was a randomized and controlled clinical trial in which individuals receiving drug abuse treatment will be recruited to participate in a multi-center HIV testing and counseling study. The study assessed the relative effectiveness of three HIV testing strategies, (1) on-site HIV rapid testing with brief, participant-tailored prevention counseling, (2) on-site HIV rapid testing with information only and (3) referral for off-site HIV testing, in increasing receipt of HIV test results.
Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs
Nicotine dependence is common among drug and alcohol dependent patients. This multi-site trial evaluated the effectiveness of smoking-cessation treatment with transdermal nicotine patch replacement (SC) as an adjunct to treatment-as-usual for illicit substance abuse (TAU). Cigarette smokers from five methadone-maintenance clinics and two drug and alcohol dependence treatment programs were randomly assigned to receive either SC as an adjunct to usual care or TAU.
Low-threshold Buprenorphine Treatment at Syringe Services Programs: a Type I Hybrid Effectiveness-implementation Trial
Funded by the NIH HEAL Initiative℠
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder: A pragmatic, multi-site, double-blind, Randomized, placebo-controlled, trial (TAB) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative℠
Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Rural Expansion of Medication Treatment for Opioid Use Disorder: Electronic Health Record Data Collection and Analysis (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Barriers and Facilitators to Engaging in Addiction Treatment among Black, Latino, and non-Latino White Patients Receiving ED-initiated Buprenorphine Treatment (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Adolescent outcomes of Post-operative opioid Exposure (APEX) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Adherence and Feasibility of Wearable Technologies and Ecological Momentary Assessment to Assess Autonomic Function and Negative Affect in Opioid Use Disorder (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative℠